Validation of residual SYNTAX score with second-generation drug-eluting stents: One-year results from the prospective multicentre SEEDS study

EuroIntervention

Volumn 10, Issue 1, 2014, Pages 65-73

  Xu, Bo ^a   Yang, Yue Jin ^a   Han, Ya Ling ^b   Lu, Shu Zheng ^c   Li, Bao ^d   Liu, Qiang ^e   Zhu, Guo Ying ^f   Cui, Jun Yu ^g   Li, Lang ^h   Zhao, Ye Lin ^a   Kirtane, Ajay J ⁱ  

^a FUWAI HOSPITAL   (China)

^b Shenyang Northern Hospital   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d Shanxi Cardiovascular Institute   (China)

^e Shenzhen Sun Yat Sen Cardiovascular Hospital   (China)

^f WUHAN ASIA HEART HOSPITAL   (China)

^g CHINESE PLA GENERAL HOSPITAL   (China)

^h GUANGXI MEDICAL UNIVERSITY   (China)

ⁱ NewYork Presbyterian Hospital   (United States)

Author keywords

Drug eluting stent; Everolimus; Long lesion; Multivessel disease; Residual SYNTAX score; Small vessel

Indexed keywords

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE SAFETY; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INSTRUMENT VALIDATION; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROSTHESIS FAILURE; SYNTAX SCORE; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; COHORT ANALYSIS; CORONARY STENOSIS; PROCEDURES; PROSPECTIVE STUDY; REPRODUCIBILITY; RESTENOSIS; TREATMENT OUTCOME; VALIDATION STUDY;

AGED; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84902316768     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV10I1A12     Document Type: Article

References (17)

1. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1:219-27.
2. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381:629-38.
3. Girasis C, Garg S, Räber L, Sarno G, Morel MA, Garcia-Garcia HM, Lüscher TF, Serruys PW, Windecker S. SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with pacliTAXel-eluting stent for coronary revascularization (SIRTAX) trial. Eur Heart J. 2011;32:3115-27.
4. Généreux P, Palmerini T, Caixeta A, Rosner G, Green P, Dressler O, Xu K, Parise H, Mehran R, Serruys PW, Stone GW. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. J Am Coll Cardiol. 2012;59:2165-74.
5. Malkin CJ, George V, Ghobrial MS, Krishnan A, Siotia A, Raina T, Morton AC, Gunn J. Residual SYNTAX score after PCI for triple vessel coronary artery disease: quantifying the adverse effect of incomplete revascularisation. EuroIntervention. 2013;8:1286-95.
6. Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, Holmes DR, Mack M, Morice MC, Stahle E, Colombo A, de Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery(SYNTAX) trial validation of the residual SYNTAX score. Circulation. 2013;128:141-51.
7. Caputo RP, Goel A, Pencina M, Cohen DJ, Kleiman NS, Yen CH, Waksman R, Tolerico P, Dhar G, Gordon P, Bach RG, Lopez JJ. Impact of drug eluting stent length on outcomes of percutaneous coronary intervention (from the EVENT registry). Am J Cardiol. 2012;110:350-5.
8. Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC Cardiovasc Interv. 2011;4:1209-15.
9. Hakeem A, Garg N, Bhatti S, Rajpurohit N, Ahmed Z, Uretsky BF. Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data. J Am Heart Assoc. 2013;2:e000354.
10. Hu SS, Kong LZ, Gao RL, Zhu ML, Wang W, Wang YJ, Wu ZS, Chen WW, Liu MB. Outline of the report on cardiovascular disease in China, 2010. Biomed Environ Sci. 2012;25:251-6.
11. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.
12. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat. 1979;7:1-26.
13. Capodanno D, Di Salvo ME, Cincotta G, Miano M, Tamburino C, Tamburino C. Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease. Circ Cardiovasc Interv. 2009;2:302-8.
14. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial. J Am Coll Cardiol. 2011;57:2389-97.
15. Wykrzykowska JJ, Garg S, Girasis C, de Vries T, Morel MA, van Es GA, Buszman P, Linke A, Ischinger T, Klauss V, Corti R, Eberli F, Wijns W, Morice MC, di Mario C, van Geuns RJ, Juni P, Windecker S, Serruys PW. Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. J Am Coll Cardiol. 2010;56:272-7.
16. Gao Z, Xu B, Yang YJ, Yuan JQ, Chen J, Chen JL, Qiao SB, Wu YJ, Yan HB, Gao RL. Long-term outcomes of complete versus incomplete revascularization after drug-eluting stent implantation in patients with multivessel coronary disease. Catheter Cardiovasc Interv. 2013;82:343-9.
17. Aggarwal V, Rajpathak S, Singh M, Romick B, Srinivas VS. Clinical outcomes based on completeness of revascularisation in patients undergoing percutaneous coronary intervention: a meta-analysis of multivessel coronary artery disease studies. EuroIntervention. 2012;7:1095-102.